Table 1.
Baseline characteristics of the randomized controlled trial population, according to treatment arm.
| Combined | Deferoxamine | p-value | |
|---|---|---|---|
| Number of patients | 32 | 33 | - |
| Age (years) | 28.8 ± 4.2 | 28.7 ± 5.3 | 0.9 |
| Gender (male) | 14 (44%) | 13 (39%) | 0.5 |
| Body surface area | 1.53 ± 0.15 | 1.56 ± 0.16 | 0.5 |
| Heart rate | 78 ± 10 | 81 ± 16 | 0.3 |
| Deferoxamine dose (mg/kg/day) | 40.6 ± 13.2 (5 days/week) | 40.5 ± 14.0 5 days/week) | 1.0 |
| CMR measures | |||
| Myocardial T2* | 11.7 (0.08) | 12.4 (0.11) | 0.3 |
| Liver T2* | 4.9 (0.52) | 4.2 (0.62) | 0.5 |
| RVEDV (mL) | 129.5 ± 30.8 | 131.8 ± 34.4 | 0.8 |
| RVESV (ml) | 52.5 ± 17.5 | 52.3 ± 18.5 | 1.0 |
| RVEF (%) | 60.2 ± 7.2 | 61.0 ± 7.1 | 0.7 |
| Echo measures | |||
| PAP (mmHg) | 22.3 ± 5.0 | 20.9 ± 5.4 | 0.4 |
| Blood measures | |||
| Transfusional red blood cell input (mL/kg/year) | 133.4 ± 34.9 | 130.2 ± 38.6 | 0.7 |
| Haemoglobin (g/L) | 106 ± 9.6 | 102 ± 9.5 | 0.1 |
| Hepatitis C positive | 23 (72%) | 26 (79%) | 0.4 |
| Serum ferritin (μg/L) | 1574 (11) | 1379 (10) | 0.5 |
| BNP (pmol/L) | 13.6 (5.6, 30.1) | 15.2 (7.3, 26.2) | 0.7 |
| Creatinine (mg/dL) | 0.77 ± 0.21 | 0.74 ± 0.23 | 0.6 |
| Cardiac medication | |||
| Any | 5 (16%) | 8 (24%) | 0.4 |
| Digoxin | 3 (9%) | 4 (12%) | 0.7 |
| ACEi/ARB | 5 (16%) | 8 (24%) | 0.4 |
| Diuretics | 3 (9%) | 5 (15%) | 0.5 |
Values are presented as n (%), mean ± SD, geometric mean (coefficient of variation), or as median (25th - 75th percentile). RV = right ventricular; EDV = end-diastolic volume; ESV = end-systolic volume; PAP = pulmonary artery systolic pressure; BNP = B-type natriuretic peptide. ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers.